Abstracts Archive - Page 2165 of 2425 - ACR Meeting Abstracts

Abstract Number: 1286 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Effects Of Tyrosine-Hydroxylase(TH)-Positive Catecholamine Producing Cells In Chronic Arthritis
Zsuzsa Jenei-Lanzl¹, Silvia Capellino², Frieder Kees³ and Rainer H. Straub⁴, ¹Department of Internal Medicine, University Hospital Regensburg, 1Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Regensburg, Germany, ²2Department of Pediatrics, Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA., Baltimore, MD, ³Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany, ⁴Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany
Background/Purpose: In previous studies we have shown that inflammatory processes in experimental arthritis are strongly affected by the sympathetic nervous system (SNS): In the early…
Abstract Number: 1287 • 2013 ACR/ARHP Annual Meeting
Pre-Clinical Proof-Of-Concept Of ALX-0761, a Nanobody^® Neutralizing Both IL-17A and F In a Cynomolgus Monkey Collagen Induced Arthritis Model
Katrien Vanheusden¹, Laurent Detalle¹, Alex Hemeryck¹, Alain Vicari², Roland Grenningloh³, Sofie Poelmans¹, Heidi Wouters⁴ and Thomas Stöhr¹, ¹Pharmacology, Ablynx NV, Gent, Belgium, ²Calypso Biotech, Geneva, Switzerland, ³Pharmacology, Merck-Serono, Darmstadt, Germany, ⁴Clinical Development, Ablynx nv, Zwijnaarde, Belgium
Background/Purpose: Interleukin (IL)-17 and Th17 cells are implicated in many auto-immune diseases, such as rheumatoid arthritis (RA), psoriasis and multiple sclerosis. Although IL-17(A) is the…
Abstract Number: 1288 • 2013 ACR/ARHP Annual Meeting
Development Of Antibodies Specific For Carbamylated Protein Precedes Disease Onset In Mice With Collagen-Induced Arthritis
Leendert A. Trouw¹, Bisheng Liu¹, Jing Shi¹, Diahann T.S.L. Jansen¹, Martin Hegen², Tom W.J. Huizinga¹, Jeroen N. Stoop¹ and René E. M. Toes¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pfizer, Cambridge, MA
Background/Purpose: Antibodies against citrullinated proteins are a characteristic of rheumatoid arthritis (RA). Recently, we demonstrated that autoantibodies recognizing homocitrulline containing proteins are present in sera…
Abstract Number: 1289 • 2013 ACR/ARHP Annual Meeting
IL-6 Is Required For Th1- and Th17- Mediated Arthritis
Alison Finnegan¹, Yanxia Cao¹ and Susan Olalekan², ¹Dept of Medicine, Rush University Medical Center, Chicago, IL, ²Immunology, Rush University Medical Center, Chicago, IL
Background/Purpose: We have reported that the route of immunization in proteoglycan-induced arthritis (PGIA) determines the T helper phenotype responsible for arthritis. Intraperitoneal (i.p.) immunization induces…
Abstract Number: 1290 • 2013 ACR/ARHP Annual Meeting
Pro-Inflammatory and Anti-Inflammatory Roles Of Interferon Regulatory Factor 5 In The Development Of Collagen-Induced Arthritis
Yoshifumi Tada¹, Syuichi Koarada¹, Rie Suematsu¹, Satoko Tashiro¹, Natsumi Nagao¹ and Akihide Ohta², ¹Rheumatology, Saga University, Saga, Japan, ²Nursing, Saga University, Saga, Japan
Background/Purpose: Interferon regulatory factor 5 (IRF5) is a transcription factor that mediates signals activated by engagement of Toll-like receptors (TLRs). IRF5 polymorphisms are associated with…
Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting
COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
Abstract Number: 1292 • 2013 ACR/ARHP Annual Meeting
The Spatial Energy Expenditure Configuration and Possible Applications In An Experimental Model Of Arthritis
Susanne Klatt¹ and Rainer H. Straub², ¹Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrine Immunology, University Hospital Regensburg, Regensburg, 93055, Germany, ²Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany
Background/Purpose: An autoimmune response with differentiation and proliferation of immune cells and the subsequent tissue-directed inflammatory process in the symptomatic phase of the disease are…
Abstract Number: 1294 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Effect Of Resveratrol As a Dietary Supplement In An Antigen-Induced Arthritis Rat Model
Romina R. Riveiro-Naveira¹, Jesus Loureiro¹, Alberto Centeno-Cortés², Eduardo López-Peláez², Carlos Vaamonde-García¹, M. Noa Valcárcel-Ares¹, Francisco J. Blanco³ and Maria J. López-Armada¹, ¹Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, ²Experimental Surgery Unit, CHU A Coruña, A Coruña, Spain, ³Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain
Background/Purpose: Inflammatory cells like macrophages, lymphocytes and neutrophils in hyperplasic synovial tissue have been identified as key players in the onset and development of rheumatoid…
Abstract Number: 1295 • 2013 ACR/ARHP Annual Meeting
Mechanisms For Fostamatinib-Induced Blood Pressure Elevation
Matthew Skinner¹, Karen Philp¹, David Lengel², Lucy Coverley¹, Eva Lamm Bergstroem³, Philip Glaves¹, Helen Musgrove¹, Helen Prior¹, Martin Braddock⁴, Russell Huby¹, Jon O Curwen¹, Paul Duffy¹ and Alex Harmer¹, ¹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ²AstraZeneca R&D Waltham, Waltham, MA, ³AstraZeneca R&D Mölndal, Mölndal, Sweden, ⁴AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom
Background/Purpose: Fostamatinib is a kinase inhibitor with activity at spleen tyrosine kinase. In clinical studies in patients with rheumatoid arthritis, fostamatinib treatment was associated with…
Abstract Number: 1255 • 2013 ACR/ARHP Annual Meeting
Ovarian Dysfunction In Adult Childhood-Onset Systemic Lupus Erythematosus Patients: A Possible Role Of Methotrexate?
Daniel B. Araujo¹, Lucas Yamakami², Eloisa Bonfá³, Vilma S. T. Viana⁴, Sandra G. Pasoto⁵, Rosa M. Pereira⁴, Paulo C. Serafin², Eduardo F. Borba⁶ and Clovis A. Silva⁷, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, ²Gynecology Department, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division; University of São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil
Background/Purpose: Reduction of ovarian reserve has been observed in childhood-onset SLE (c-SLE) and adult SLE populations, and most of them were limited to follicle stimulating…
Abstract Number: 1256 • 2013 ACR/ARHP Annual Meeting
Depression, Anxiety and Suicidal Thoughts In a Cohort Of Pediatric Lupus and Mixed Connective Tissue Disease Patients
Andrea Knight¹, Pamela F. Weiss², Knashawn Morales³ and Ron Keren⁴, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Emerging data reveals that depression and anxiety disorders are highly prevalent in adult patients with systemic lupus erythematosus (SLE). These disorders are associated with…
Abstract Number: 1257 • 2013 ACR/ARHP Annual Meeting
Feasibility and Clinical Implications Of The Pediatric Automated Neuropsychological Assessment Metrics for Screening Of Childhood-Onset Neuropsychiatric Systemic Lupus Erythematosus
Patricia Vega-Fernandez¹, Natasha M. Ruth², Deborah M. Levy³, Frank Zelko⁴, Eyal Muscal⁵, Marisa S. Klein-Gitelman⁶, HaiMei Liu⁷, Adam Huber⁸, Jiha Lee⁹, Jessica Hummel⁹, Lori B. Tucker¹⁰, Tresa Roebuck-Spencer¹¹ and Hermine Brunner^12,13, ¹Division of Rheumatology, Cincinanti Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Pediatric Neuropsychology Service, Children's Memorial Hospital, Chicago, IL, ⁵TCH Pediatric Rheum Center, Baylor College of Medicine, Houston, TX, ⁶Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁷Children's Hospital of Fundan University, Shanghai, China, ⁸IWK Health Centre, Halifax, NS, Canada, ⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ¹¹Cognitive Science Research Center, University of Oklahoma, Norman, OK, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Neuropsychiatric disease is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Signs of cNPSLE can be subtle and difficult to ascertain in daily clinical practice.…
Abstract Number: 1258 • 2013 ACR/ARHP Annual Meeting
Cognitive Functions In Childhood-Onset Systemic Lupus Erythematosus
Bruna Bellini¹, Cleonice de Souza¹, Mariana Postal¹, Nailu A. Sinicato¹, Paula T Fernandes², Roberto Marini³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Faculty of Physical Education, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: To determine differences in cognitive functions in childhood-onset systemic lupus erythematosus (cSLE). Methods: We performed a cross-sectional study including patients with age of onset…
Abstract Number: 1259 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction In Childhood Systemic Lupus Erythematosus: Comparison Of Different Classification Criteria
Bruna Bellini¹, Cleonice de Souza¹, Mariana Postal¹, Nailu A. Sinicato¹, Roberto Marini², Paula T Fernandes³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²State University of Campinas, Campinas, Brazil, ³Faculty of Physical Education, State University of Campinas, Campinas, Brazil, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Cognitive deficits are frequently observed in systemic lupus erythematosus (SLE), in both adult and childhood (cSLE) onset. However there are several different cutoff levels…
Abstract Number: 1260 • 2013 ACR/ARHP Annual Meeting
Serum S100β Is Associated With Neuropsychiatric Manifestations In Childhood-Onset Systemic Lupus Erythematosus
Aline T. Lapa¹, Mariana Postal¹, Nailu A. Sinicato¹, Bruna Bellini¹, Paula T Fernandes², Roberto Marini³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Faculty of Physical Education, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Involvement of the central nervous system (CNS) in systemic lupus erythematosus (SLE) is an important source of morbidity and mortality. S100β has been considered…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].